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Synthetic biology involves using interchangeable DNA sequences to genetically 
engineer organisms in new ways.   In this paper I use the annual International 
Genetically Engineered Machines (IGEM) undergraduate student competition at MIT 
as a case study to examine ways in which synthetic biologists, several of whom were 
originally pioneers in software and computing, have attempted to establish this field.  
In particular, they have emphasised open source science and technology, the ‘private 
collective’ innovation model and interdisciplinary team-working.  The registry of 
standard biological parts (‘BioBricks’), featured in the competition and maintained by 
MIT, is a good example of this open source approach to science.  BioBricks are freely 
and publicly accessible, allowing research to develop quickly, and at relatively low 
cost.  Notably, one student team used BioBricks in their project to engineer e-coli to 
recognise arsenic, which could be used for low-cost water testing in countries like 
Bangladesh, where many wells are arsenic polluted.  At the same time, there are 
concerns about some aspects of the development of such tools and their potential for 
bioterrorism.  Interviews with key scientists and engineers who established the 
competition and students who have taken part form the basis of the dataset.   
INTRODUCTION 
It has been said that we are living in the century of biology.  Synthetic biology is 
emerging as the exemplar of this brave new world where the DNA of simple 
organisms, such as bacteria and yeast, can be engineered to perform new functions 
with potential applications across many sectors including pharmaceuticals, energy and 
computing.  Researchers have identified at least two approaches to synthetic biology 
(O’Malley, et al., 2007).  The most high profile is in synthetic genomics and 
exemplified by Craig Venter and his team’s development of the first synthetic 
chromosome with the ultimate aim of developing a sustainable form of hydrogen.  
The second is based on BioBricks, standard biological parts that can be linked and 
inserted into the genomes of organisms, originally invented and then further 
developed by Tom Knight and his colleagues at MIT.  This paper is focused on the 
latter, and examines the genesis of the BioBrick approach to synthetic biology. 
 
In this paper I argue that the BioBricks represents a unique way to build a new field of 
scientific enquiry, which emerges from Knight’s background as a computer engineer, 
who only late in his career turned to biology, and his experience as a teacher and 
student at MIT.  It is based on the idea of using student competitions to establish and 
grow a science.  Knight along with Randy Rettberg and Drew Endy developed the 
International Genetically Engineered Machines Competition (IGEM), in which 
undergraduate students work in interdisciplinary teams over the course of a summer 
using BioBricks to build biological machines with a faculty supervisor.  The students 
are from a variety of backgrounds, biology, engineering, and bioinformatics 
contributing their own expertise to building the machine, and teaching each other, and 
their faculty advisors, relevant aspects of their disciplines to progress the development 
of the machine as the whole.  At the end of the summer, students develop a wide 
range of applications, some serious (cancer stickybots – bacteria that recognize colon 
cancer cells stick to them and commit suicide) and some whimsical (knocking out the 
metabolic path that make e. coli smell like faeces and inserting new ones that make 
the bacteria smell like bananas and mint), but throughout the competition and the 
IGEM Jamboree, the student conference at which work is presented, there is a sense 
of play and humour.  In the course of their work, students develop new BioBricks, 
such as sequences for cell death, light recognition, and pattern formation, which are 
then uploaded to the Registry of Standard Biological Parts (‘the Registry’) at MIT, an 
open source database that is made available to other students and researchers; an anti-
patent approach is another unique feature of BioBricks.  Once students complete 
IGEM, many go on to do masters degrees and doctorates in the field.  As a whole the 
field is very young; most of its key scientists are under the age of 45.  Knight and his 
colleagues made a conscious decision to develop the field from the bottom up because 
the BioBricks approach was seen to be so unconventional and interdisciplinary 
blending biology and engineering that it would be difficult to get established scholars 
involved.  It has been successful; the IGEM competition has grown rapidly as has the 
Registry, and the first generation of students that attended IGEM as undergraduates 
are completing their doctorates and entering academe having used the Registry in 
their research.   
 
The BioBricks model is interesting as well in the ways in which it has addressed 
social engagement, which it has attempted to blend with the rest of the scientific 
agenda, though not always very successfully, in IGEM and in the conferences the 
BioBricks Foundation sponsors, such as SB 1.0-4.0, involving social scientists and 
NGOs voicing concern.  
 
The purpose of this paper is to explore critically the model of knowledge generation 
used in BioBricks, looking in particular at its genesis in biological computing, the 
private-collective (or open source) innovation model, interdisciplinarity and 
engagement with social concerns particularly around biosafety but also increasingly 
of corporate control.  It is likely that whereas once BioBricks, IGEM and the Registry 
were inextricably intertwined, that they are increasingly becoming disaggregated as 
synthetic biology as a field grows and more investment is made available both from 
public and private sources.   The BioBricks model of growing the field of synthetic 
biology breaks down traditional boundaries of research and teaching, biology and 
engineering, open and closed source knowledge, and the nature of disciplinary 
knowledge and expertise, and synthetic biology itself erodes the distinction between 
life and machine (see also Fujimura, 2005).  As it does so it raises concerns for social 
movement organisations about regulation and the sanctity of life, which the BioBricks 
community has attempted to deal with by advocating self governance.  So far this has 
been a successful strategy, but the true test of this will be when the first BioBrick 
products are ready to be produced because it is likely to be some time yet before they 
are made available.  
 
TOM KNIGHT AND THE INVENTION OF BIOBRICKS 
Knight has spent most of his life at MIT.  He began working there at the age of 14 as 
a high school student, when he secured a job as an electrical engineer in the artificial 
intelligence lab.  Much of his career was spent as an electrical engineer, where he 
designed and built lisp, or Knight, machines, which were the first single use 
computers and paved the way for the commercialisation of laser printers, Windows 
operating systems and the computer mouse.  He also worked on Arapnet (the 
precursor to the internet), interfaces and designed the ‘packets’ data transfer system, 
which is the basis for information transfer in the internet.  As an electrical engineer, 
he believed Moore’s Law, the idea that computer power grows exponentially, had its 
limits and that the atomic scale was fast being reached in silicon chip-based computer 
circuit designs.  In the early 1990s, increasingly bored by traditional computer 
engineering and dissatisfied with its limits, he read Harold Morowitz’s work, a 
physicist who later became a biologist, who worked on mollicutes, which are a type of 
very small organism that only contain a billion atoms.  Knight reflected “Morowitz’s 
work laid out, in words I could understand as an engineer, an agenda that seemed so 
exciting I had to go with it.  Here’s a class of organisms so simple that maybe we can 
understand everything there is to know about them” (Knight quoted in Morton, 2005).  
But as a computer engineer he was ultimately imagining a time when computers 
would move from physical to biological systems.  A key moment came when he 
realised that a teaspoon of programmable bacteria could have a million times more 
memory than the world’s largest computers, and potentially more speed than many 
billions of processors.  As Knight says ‘There is one megabyte of information in 
something the size of a cell.  But not only that, it divides, which no other engineering 
system does, so you end up with an Intel processor along with the factory that makes 
them.’  (Tom Knight, interview) 
 
Underpinning this is the idea held by those at the artificial intelligence lab at MIT for 
some time that machine intelligence will only come from millions of small computers 
that are interlinked, rather than from one large computer.  This is analogous to the 
workings of the neural networks that comprise the brain.   
 
To begin the switch, Knight began taking biology classes in 1993, while 
simultaneously teaching electrical engineering and talking with the MIT Artificial 
Intelligence Lab funders, the Defence Advanced Research Project Agency (DARPA), 
about biological information-processing systems.  In 1995 he received funding from 
DARPA to begin building a molecular biology lab in the artificial intelligence 
department.  The next year he began experiments, and as an engineer was increasingly 
frustrated with the lack of standardization in biology, saying that  ‘biologists talk 
about having “good hands” in the lab, and everyone does experiments in different 
ways.  When you put two pieces of DNA together you need a standard way of doing 
this’ (Tom Knight, interview).    Knight likens this stage of the engineering of biology 
to the point of the industrial revolution in 1864 when screw threads were standardised, 
allowing for mass production of goods.  
 
In 1999 Knight invented BioBricks, a standard for DNA, with identical restriction 
enzyme structures, allowing DNA strands to be ‘snapped’ together and assembled 
similar to children’s Lego blocks.  BioBricks are the electrical engineering of biology, 
working in analogous ways to key components in that field, logic gates, switches and 
clocks, which are interchangeable.  The ‘current’ is the rate at which RNA 
polymerase, the molecule that transcribes DNA into mRNA, moves along the DNA 
strand.  Knight developed the first six BioBricks, and uploaded them to the Registry 
in 2001. 
 
Drew Endy came to MIT as a new recruit in 2002, with a background in civil 
engineering he began studying molecular biology as part of his PhD, which was a 
computer model of a virus that infects E. coli; he was looking at processes that occur 
as the virus infects the bacteria. To test the model, he rearranged the virus’ DNA so 
that proteins would be synthesised in a different order, then used the model to try to 
predict what would happen when the virus encountered E. coli.  But in the lab the 
virus and E. coli would behave unpredictably, which he found frustrating.   Following 
his PhD he went to work for a research institute in Berkeley where he was encouraged 
to take a traditional biological approach and “go back and understand a whole bunch 
more about the science of the organism in order to model it better…which is a fine 
and valid traditional path’ (Endy cited in Morton, 2005).  Instead he decided to ‘build 
new biological systems – systems that are easier to understand because we made them 
that way.’ 
 
Developments of the technology allowing both the reading and writing (synthesis) of 
DNA sequences, partly as a result of the human genome project, were becoming 
possible by 2000, at which point the capacity of machines to read DNA was doubling 
every 18 months.  Such “Carlson curves” predicted that by 2010 lab worker would be 
able to write and synthesise sequences for two human genomes each day (Morton, 
2005). 
 
Endy foresaw the beginning of an era where biology is no longer exclusively studied 
by examining natural systems, and looked for responses to his notion that ‘we should 
rebuild the natural biological systems we most care about and domesticate their 
genomes’, his only ‘coherent’ response to this request was said to be from Tom 
Knight at MIT. 
IGEM 
Knight’s next innovation was to develop the Registry and the BioBrick approach to 
synthetic biology via undergraduate student projects and competitions, first at MIT in 
the January term then as part of a 10 week project in the summer.  Knight brought 
Randy Rettberg from Sun Microsystems to MIT who, along with Knight and Endy, 
developed IGEM.  IGEM was developed based on the model of Lynn Conway’s 1978 
MIT course on very-large scale integration (VLSI), which Knight attended.  Conway, 
a computer scientist from XEROX and Carver Mead from Caltech had developed a 
method for decoupling silicon chip design from manufacturing, which was an 
important innovation at the time as it allowed designers to map circuits without 
having to manufacture them.  Chip design and manufacture had previously been 
restricted to major corporations that had foundries.  Students for the first time were 
not only able to learn VLSI, they were able to design circuits and have them built.  
Upon designing circuits they sent their plans via Arapnet to a chip foundry in 
California, which sent the chips back a month later.  Out of this pedagogic model 
emerged student projects that enabled the cellular telephone, palmtop computers and 
games consoles (reference).   
 
Knight and Endy based their Independent Activities Period class at MIT in January on 
the earlier VLSI course.  Students were to design DNA circuits, sequences coding for 
certain proteins, and sites for proteins to bind and therefore turn genes on or off.  
Their sequences would then be emailed to Blue Heron, a gene synthesis company in 
Seattle, and the DNA would be mailed to MIT and inserted into E. Coli.  DARPA 
funded the synthesis, as it had funded the chip production for Conway decades before. 
 
The first MIT synthetic biology competition started in 2004 with the question ‘Can 
simple biological systems be built from standard interchangeable parts and operated 
in living cells?’  BioBricks were made available to students from the Registry, and 
students were encouraged to develop their own and upload them to the Registry.  In 
2004 there were 5 teams from US universities, in 2005 the first International 
Genetically Engineered Machines Competition (IGEM) had 13 teams from 4 
countries, in 2006, there were 37 teams from 15 countries, and in 2007 there were 54 
teams and hundreds of competitors from all over the world.  Among the projects 
already mentioned, students have also developed bacteria engineered to recognize 
light and respond to form pictures, and an arsenic biosensor in which bacteria have 
been engineered to change colour in the presence of arsenic, which could be 
extremely valuable for developing countries like Bangladesh where wells have high 
rates of natural arsenic contamination. 
 
A NEW SCIENCE DEVELOPED THROUGH UNDERGRADUATE WORK 
IGEM has been the basis for developing the BioBrick approach to synthetic biology, 
destabilising traditional notions of expertise and learning.  In 2007 Endy was quoted 
as saying ‘One of the most amazing things about the jamboree this year was how 
much I was able to learn’.  Also Craig Venter, who is not a part of IGEM but who is 
critical of pedagogical traditions in biology said ‘The way biology is normally taught, 
it comes across as pretty dismal – you memorise lots of facts than then you regurgitate 
them…[IGEM] approaches things from a problem-solving and design perspective.  
That I think is a huge leap forward’. (Endy and Venter cited in Trivedi, 2007) 
 
IGEM also challenges traditional notions of expertise, as the students work in 
interdisciplinary teams teaching each other what they need to know to build the 
machine. 
‘That was the startling thing for me out of IGEM, when we suddenly have 3 
biologists and 3 engineers in the same room, undergrads, and I didn’t realise 
the difference the different schooling had on our ways of thinking, our ways of 
approaching problems. It was really revealing to me, I had never really 
considered it before. It was kind of like, we were all at the same university, 
we’ve all gone through the same educational system, just because that 
gentleman’s studying natural science shouldn’t mean he should be any less 
intelligent or think in any other way than I do. And because he is an engineer 
he thinks about problems from a very different perspective. But the great thing 
about IGEM was that by the end of the summer we’d both traded almost 
methods, to the point where we had both approaches.’ (Interview, IGEM 
Student) 
 
Students also teach their faculty as well as the other way around.  Tito Jankowski a 
member of a team from Brown said ‘Synthetic biology is new to the faculty; they 
didn’t grow up with it.  Collectively our team knows a lot more than our advisers.’  
Faculty members agree, Gary Wessel, his advisor reflected ‘We are a different 
generation, and we were trained to compartmentalise our education to the point where 
we excluded anything that wasn’t specifically in our domain.’ (cited in Trivedi, 2007)   
 
Randy Rettberg, the current director of IGEM, describes his conceptualisation of 
building the BioBricks approach along with his pedagogical philosophy as:  
‘What I’m trying to do is put back some courage into the undergraduates the 
idea that they should trust themselves. And then, I’m trying to teach the 
instructors that if you do that you’ll learn from them.  It has really happened 
that, as a result of doing IGEM, the instructors themselves have learned 
absolutely critical things.  In the end, after about 2 months, the students can 
outdo the instructors. The students have 500 parts [from the Registry], as 
opposed to the instructor’s one or two, and the students are saying “what shall 
we put together”?  The students now can do what I as a professor can’t do. 
Boy that was weird! I’m starting to have a fair number of professors who 
started saying “could you send me some of the parts you sent out to the IGEM 
teams for my lab?” So, it’s starting to move to that next step.’ (Randy 
Rettberg, interview). 
 
As the BioBricks approach to synthetic biology develops, and as students begin to 
move through from undergraduate to graduate and finally to research positions, the 
links between IGEM, the Registry, and the BioBricks community become 
increasingly disaggregated. 
‘If we’d have had this conversation a year ago, the registry, synthetic biology 
and IGEM were so tightly inter-wrapped that it was very difficult to explain to 
someone that didn’t have any knowledge of it, the differences. They’re self-
reliant and they encompass each other. What has happened I think, in the last 
year, very slightly, and it’s still very much part and parcel, is that they’ve 
pulled away a little bit. The registry is the registry in its own right, it has labs 
using it, I’m using it now for example to do my PhD, and I have nothing to do 
with IGEM, in that respect. There are grad students at MIT, people all over the 
world now are starting to use BioBricks. Even indirectly. We’re distributing 
fluorescent proteins for example. [Recipients] don’t really get the fact that 
they’re BioBricks, they just know that they’ve got fluorescent proteins with 
restriction sites on the end. And that’s part of the idea of the society that we 
want to promote; we’ve got tools to give people and they can start to get 
around to that way of thinking and see the power of it, then we’ll hopefully 
grow a community here.’ (Interview, IGEM student)  
 
BREAKING DOWN DOMAINS IN SCIENCE AND TECHNOLOGY 
The breaking down of domains that the BioBricks approach represents evokes 
research on the importance of boundary work in science, between disciplines and 
types of expert knowledge (Gieryn, 1999; Jasanoff, 1990; Thrift, 1996).  This 
literature drew originally from Foucault who focused on spatial aspects of knowledge 
boundaries, which were important in the formation of academic disciplines. ‘Once 
knowledge can be analysed in terms of religion, domain, implantation, displacement, 
transposition, one is able to capture the process by which knowledge functions as a 
form of power and disseminates the effects of power.’ (Foucault, 1980: 69)  For 
Foucault, then, knowledge, which carries with it power, is not only spatial but also 
social and historical.  The concept of discourse, what is thought said or acted upon in 
any historical period, provides an analytical tool to assess what is seen as knowledge 
its attendant power dynamics, which can be applied to any field of knowledge 
including those in science.  For example, madness could only be seen as divinely or 
diabolically inspired in the Middle Ages, and it could only be seen as a medical 
problem in the late twentieth century.  Actors, scientists and others must operate 
within the discursive reality of the epoch in which they find themselves.  Foucault 
sees boundary creation in the genesis of science ‘What was striking in the 
epistemological mutations and transformations of the seventeenth century is to see 
how the spatialization of knowledge was one of the factors in the constitution of 
knowledge as science’ (Foucault, 1984: 254).   
 
The creation of boundaries is part of a social dynamic: 
 “The spatializing descriptions of discursive realities gives on to the analysis 
of related effects of power…[T]he formation of discourses and the genealogy 
of knowledge need to be analysed, not in terms of types of consciousness, 
modes of perception and forms of ideology, but in terms of tactics and 
strategies of power…deployed through…demarcations, control of territories 
and organizations of domains.” (Foucault, 1980: 70-1; 77) 
 
Bourdieu’s concept of a force field usefully theorises a space where social contests 
take place involving definitions of science.  
“What is at stake is in fact the power to impose the definition of science (i.e. 
the delimitation of the field of problems, methods and theories that may be 
regarded as scientific)…The definition of what is at stake in the scientific 
struggle is thus one of the issues at stake in the social struggle.” (Bourdieu, 
1975: 23-4)  
  
Kuhn’s structure of scientific revolutions (1962) though written before Gieryn, 
Foucault and Bourdieu, anticipates many of these points, as well as Latour, in 
focusing on ideas that are thinkable, and intellectual strategies that are available in 
particular historical epochs, while stressing their social rootedness and attendant 
social contests, and is applicable to the way Knight and others developed the BioBrick 
approach to synthetic biology.  For Kuhn, a goal of science is to construct models, or 
paradigms, that will account for as much empirical data as possible.   As paradigms 
are pushed, anomalies, cases that do not fit with the model, appear.  Some within a 
group of scientists will see that there is a problem, or crisis, and pursue what Kuhn 
called revolutionary science, which is the exploration of alternatives to taken for 
granted assumptions.  The new paradigm appears beset by anomalies due to its lack of 
development, and most of the traditional scientific community will reject the new 
paradigm until there is enough evidence to support it.  For a paradigm to be accepted 
‘First, the new candidate must seem to resolve some outstanding and generally 
recognized problem that can be met in no other way.  Second the new paradigm must 
promise to preserve a relatively large part of the concrete problem solving activity 
that has accrued to science through its predecessors’ (Kuhn, 1962: 168).  This is 
apparent in the discourse of synthetic biologists.  In the words of a Caltech 
engineering professor ‘what I cannot create I cannot understand’.  This is the 
approach that Drew Endy and Tom Knight take to synthetic biology, which traditional 
biology has not been able to resolve: that of building a living organism from scratch 
in order to understand it, so by applying engineering principles to biology, they both 
draw on the two disciplines while creating the new field of synthetic biology.  It 
should be noted that building organisms from scratch by snapping together BioBricks 
is a distinctive approach to synthetic biology; others such as Jay Keasling take 
existing organisms, and rework metabolic pathways to produce specific products such 
as arteseminin or biofuels; and Craig Venter’s synthetic genomics approach is to build 
wholly new, but minimal, genomes designed to do specific things. 
 
Paul Rabinow has characterised the views BioBricks synthetic biologists as: 
‘Everything that came before in biology was interesting and things were 
learnt, but it was not yet engineering, and not yet therefore able to achieve the 
kind of control over biological processes that this new discipline was able to 
achieve.  The big question here of course is whether or not living systems are 
analogically close enough to the electronics industry, or indeed to the vision of 
nineteenth-century engineering and the standardized screw, to be directly 
applicable.  Can the basic biological, evolutionary, non-linear aspects of living 
systems be engineered out?’ (Rabinow in Lentzos, et al., 2008: 315) 
 
PRIVATE-COLLECTIVE INNOVATION MODEL 
Underlying the BioBricks approach is a tension between two models of innovation, 
the ‘private investment’ model based on returns to the innovator from private goods 
and protection of intellectual property, and the ‘collective action’ model, which refers 
to the collaboration of innovators in order to produce public good (von Hippel and 
von Krogh, 2003).  Practices in open source software, on which the BioBricks 
approach is based have a history that stretches back to the 1960s and 1970s.  
Scientists and engineers working in the public and private sector would often share, 
modify and build upon software and share it among colleagues, and Arapnet allowed 
developers to share code more widely and cheaply.  This communal approach to 
‘hacker’ culture, originally a positive term referring to talented programmers, was 
predominant at the Artificial Intelligence laboratory at MIT in the 60s and 70s (Levy, 
1984).  
 
MIT in the 1980s licensed some of the code written by its hackers to a commercial 
firm, which then restricted access to the ‘source code’ of the software, effectively a 
key that allows a hacker to use and modify a software program, to its own personnel 
when many of the MIT hackers had been involved in writing it.  Richard Stallman, 
one of faculty in the Artificial Intelligence lab, was troubled by this as well as the 
trend towards proprietary software packages that could not be modified.  ‘Stallman 
viewed these practices as morally wrong impingements upon the rights of software 
users to freely learn and create.’ (von Hippel and von Krogh, 2003: 210)  As a result, 
in 1985 he established the Free Software Foundation, which aimed to establish a legal 
means to retain free access to software created by hackers, which was protected by 
copyright law.  Those who wrote software and wanted to protect free access to it 
could use their copyright to provide licences and guarantee rights to future users.  The 
licence Stallman developed is the General Public Licence, sometimes called 
‘copyleft’, a wordplay on copyright.  It allows those who have a copy of the software 
rights to use it for free, examine its source code, change it, and distribute original or 
modified versions without cost.   
 
Tom Knight is a product of this history at MIT, and IGEM and the Registry of 
Standard Biological Parts are based on the same open source approach to knowledge 
that was developed for software.  The BioBricks Foundation has created a public 
licence allowing BioBricks to be protected as freely available genetic parts.  This is 
based on the ‘private-collective innovation model’, which combines aspects of private 
investment with collective action (von Hippel and von Krogh, 2003).  Developers 
invest their own time and resources to develop a product, either a BioBrick or 
software code, and while they could claim rights over what they produce, they instead 
upload it to a common source and provide it to the public for free, which results in 
new knowledge essentially being provided at no cost.  This raises the question of why 
developers should provide their intellectual products for free.     
 
The goal of open source in the case of the Registry is to give away information on low 
level material, parts, while focusing on the creation and enforcement of intellectual 
property rights on complex products.  In computer terms, Intel might patent its 
processor, but not the widely used and fundamental circuitry that is used throughout 
the computer industry, which is used in the processor.  This practice of patenting high 
level material and making low level material freely available occurs in parts of the 
computer industry, but not in the pharmaceutical and biotechnology industries, which 
tend to patent more vigorously and then hold on to patents so the intellectual property 
(IP) cannot be used by others.  This is understandable when it costs $1 billion to 
develop and market a drug and companies need to recoup their investment.  Jay 
Keasling, a synthetic biologist from Berkeley who received a grant for $43 million 
from the Gates Foundation to develop a low cost way to produce artemesinin, an anti-
malarial, from yeast, and is also part of the BioBrick Foundation, has argued that ‘if 
you’re going to develop drugs for the developing world you cannot afford to pay 
those royalties.  And so we say: “Look, nobody’s really going to make any serious 
money off of these small components.  The money is in the big applications.  So let’s 
make a lot of small components and have them available as open source to everyone.”  
People can still patent the big applications – a lot of integrated components – but let’s 
at least have the components available as open source so everybody gets equal access, 
and that will further the field of engineering biology.’ (Keasling cited in Zimmer, 
2007) 
 
In this case, users of BioBricks, who are also the innovators, freely reveal DNA 
sequences.  There is no commercial market for BioBricks as they are available to 
anyone.  Innovators gain through widespread open dissemination as sequences are 
made available through the Registry, which is publicly accessible on the worldwide 
web.  The innovators are mostly students who are not commercial rivals.  The 
synthetic biology community is still fairly small, and many people know each other’s 
work.  Personal enjoyment and learning are motivating forces for those involved as 
well as the sense of well-being that comes from being part of a collective endeavour.  
The students also have a relatively high degree of personal autonomy and control over 
their creations.  However there is also a tension around free riding; benefitting from 
public access to BioBricks, without contributing to the Registry.  What is important 
here for the proponents of open source approaches is the embedding of hacker cultural 
expectations in students, which may work as long as the synthetic biology community 
is small and people know each other.  Axelrod (1984) found that in testing this kind of 
dynamic through a prisoner’s dilemma the reward for cooperation is higher than 
defection where there is no fixed end-point, which is why he suggests that where 
people see themselves as part of a project that is connected with a long term 
cooperative community endeavour that such endeavours are more likely to be 
successful.   
 
Problems with associated with the private-collective model have already begun to 
arise with student participants in IGEM, as one informant said: 
‘The open source thing is a wonderful principle, but in practice it doesn’t 
always work, and IGEM has shown that. There were labs this summer that 
weren’t prepared to share their stuff. You get the other attitude which is, 
“we’re happy to take but we’re not willing to give”; we saw that at a few 
schools. “Isn’t this a wonderful resource, we’ll use these”, completely blind to 
the fact that when they turn round and say, “No, this is our IP, we’re patenting 
this, we’re going to do this, and are not prepared to put it in the Registry.”  
That raises all kinds of questions about the open source nature and whether it’s 
sustainable and whether it will work. Because, at this early stage, it’s all well 
and good but will it be able to remain like that? People will ultimately try and 
make money; people will ultimately try and patent ideas.’ (Interview, IGEM 
Student) 
 
REGULATING SYNTHETIC BIOLOGY 
The freedom that open source engenders is something that concerns some about 
synthetic biology.  Researchers at SUNY Stony Brook created a polio virus 
synthetically in 2002, and those at the Centre for Disease Control synthesised the 
Spanish flu in 2005.  Currently synthetic biology is self-governing, Blue Heron and 
other companies check for known pathogenic sequences, however a Guardian 
journalist in 2007 was able to obtain a sequence from a known pathogen from a gene 
synthesis company, so clearly these mechanisms are not fail safe (reference).  Though 
it is possible, many synthetic biologists think the risk of bioterror is low.  As one 
scientist interviewed for this research said ‘if I wanted to kill a lot of people there are 
much easier ways to do it; I’d probably just poison the water supply rather than use 
synthetic biology’ (Synthetic Biologist Interview).  Jay Keasling similarly said ‘If I 
wanted to do evil and harm, I probably wouldn’t choose biology to do it.  It’s damn 
complicated.  Anyone sophisticated enough to know how to use these biological 
components that we’re making freely available would have been able to do it anyway, 
to some extent.’  It is also why synthetic biologists have focused on self regulation, by 
engaging with such issues within the community.  According to Keasling ’If we 
choose to regulate the industry, we have to be willing to pay the price for that, which 
means there won’t be cheap antimalarial drugs developed and there won’t be potential 
biofuels developed and other drugs for other diseases and cleaning up the 
environment and all the things that come from this area.’ (Keasling cited in Zimmer, 
2007)  That said synthetic biologists are well aware of potential dangers from misuse 
of the technology.  As Drew Endy told one group of graduating IGEMers ‘Imagine 
when the next biological attack happens…we’ll have one in the future eventually 
using a BioBrick.  The most important thing to be prepared for, when that happens, I 
think is to make sure that our countries do not re-militarise biology, because we can’t 
afford that for reasons that are obvious.  There’s so much you can do that’s harmful.’  
(Endy, 2007) 
 
Endy describes his reasons for engaging with regulatory, biosafety and public 
attitudes aspects of the technology as  
‘my interest in biosecurity issues, my interest in the ownership, sharing and 
innovation framework, and my interest in the community and its organization 
all have to do with the practical limitations I’ve encountered to do the work 
that I think is important.  I’d like to say there’s some noble instinct…but in 
practice I’m driven to go talk to …many… people because, if I don’t the 
things I’m trying to do will never become possible.  They’ll just be dead in the 
ground.  So the issues of human practice occupy my time, and perhaps even 
the majority of my time, simply because they are the greatest limiting factors.’ 
(Endy, 2008: 321-2) 
 
Paul Rabinow (2008) has critiqued the notion that benign self regulation by synthetic 
biologists, along the lines of the so-called Asilomar conference on rDNA in 1975 is 
possible today.  He suggests that there are several ways in which life is now different 
from the 1970s.  The main difference has been globalisation and growth of science, 
with many thousands of world-class scientists.  Second the internet has allowed 
production and dissemination of scientific and technological knowledge, which is not 
restricted to a select few.  Third, we live in a security environment that goes beyond 
safety (Rabinow in Lentzos, et al., 2008: 320).  Fourth, as Gaymon Bennett points out, 
industry is involved in funding science more than ever before, with ‘the power of 
industry to make claims on what counts as science’ (Bennett in Lentzos, et al., 2008: 
320).  This is the basis of the ETC group’s critique of synthetic biology; British 
Petroleum for example recently invested $500 million in synthetic biology research at 
UC Berkeley.  There are many joint ventures between energy companies, 
agribusiness, chemical, pharmaceutical, automobile and synthetic biology companies 
and involves major companies such as DuPont (chemicals), Tate & Lyle (sugar), 
ConocoPhilips (energy), Shell (energy), General Motors (automotive),  Syngenta 
(biotechnology), Monsanto (biotechnology), Bristol-Meyers Squibb 
(pharmaceuticals), Chevron (energy) as well as the US Department of Energy (ETC, 
2008).  The critique is based on the capitalist appropriation of biomass to develop the 
post petroleum economy that synthetic biology is said to deliver, and the effects this 




In an earlier introduction to synthetic biology ETC (2007) also criticised suggested 
that synthetic biologists were playing God without accountability.  ‘Today scientists 
aren’t just mapping genomes and manipulating genes, they’re building life from 
scratch – and they’re doing it in the absence of societal debate and regulatory 
oversight.  Dubbed “genetic engineering on steroids”, the social, environmental and 
bio-weapons threats of synthetic biology surpass the possible dangers and abuses of 
biotech’ (Thomas, 2007: 1).  When Keasling is asked whether he’s playing God by 
creating new life forms he responds ‘ it’s easy to say those kinds of things when you 
don’t have malaria.  It’s quite another thing when you’re ill and don’t have the means 
to come by effective, safe drugs’ (Keasling cited in Zimmer, 2007).   The ETC 
response is ‘Advocates insist that synthetic biology is the key to cheap biofuels, a cure 
for malaria and climate change remediation – media friendly goals that aim to mollify 
public concerns about a dangerous and controversial technology.  Ultimately, 
synthetic biology means cheaper and widely accessible tools to build bioweapons, 
virulent pathogens and artificial organisms that could pose grave threats to people and 
the planet.  The danger is not just bio-terror but “bio-error”’.  (ETC, 2007: 1)  
 
CONCLUSION 
This paper has illustrated how the BioBricks approach to synthetic biology was 
conceived and developed, focusing on its boundary-crossing nature, and the way it 
destabilises notions of discipline, access, and pedagogy, focusing on the unique 
method by which its founders developed a new scientific field.  It also outlined many 
of the challenges faced the synthetic biology as it grows.  As biological products get 
closer to market, synthetic biologists and publics will have to engage with the private 
versus public aspects of intellectual property, regulatory and ethical questions 
attendant with the technology.  Synthetic biologists have built in public engagement 
with the development of the field, and continued commitment to legitimacy, through 
governance structures, will be crucial if the field is to enjoy public support, 
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